Dr Annaïg Bertho is a post-doctoral researcher in the “New Approaches in Radiotherapy” team, led by the doctor Yolanda Prezado at Curie Institute, France. She joins this multidisciplinary team as a radiobiologist with the aim of strengthening and energizing their research program in radiobiology on the response of tumoral and healthy tissues to spatially fractionated radiation therapy and in particular proton minibeams radiation therapy. Her current research goal is to highlight the involvement of the immune system in the response to minibeams radiation therapy.

Dr. Elke Beyreuther finished her study on Applied Natural Sciences with a Diploma in 2005 and moved to Helmholtz-Zentrum Dresden-Rossendorf for PhD studies dealing with radiobiological cell studies at various radiation sources. After receiving her PhD in 2010 she became a scientist at HZDR/OncoRay focussing on small animal in vivo experiments with protons and on the investigation of radiobiological effects of ultra-high dose rates. This includes radiobiological studies at a clinical cyclotron as well as at different research accelerators and laser driven particle beams.

I’m a certified medical physicist with clinical expertise in photon, proton and carbon ion beam therapy and experience with the commissioning of new treatment units. My research interests include treatment planning, Monte Carlo, biological modelling, and FLASH RT with a focus on electron beams.

Marco Borghesi is Professor of Plasma Physics at the Queen’s University of Belfast, where he is employed as an academic since 1999, and he is the director of the Centre for Plasma Physics since 2017. After undergraduate studies in Italy (Laurea in Physics at Pisa University, and PGDip in Optical Technologies at AILUN, Nuoro), he obtained a PhD in Plasma Physics at Imperial College London in 1998. His research interests lay in the area of intense laser-plasma interactions, with particular expertise in laser-driven acceleration of ion beams. He has led as PI large UK-wide EPSRC projects such as LIBRA (Basic Technology, 2007-12) and more recently A-SAIL (Programme Grant, 2013-20), aimed to the advancement of laser-ion acceleration towards future medical applications. Within these projects, he has provided key contributions to the development of innovative ion acceleration schemes, and of ultra-high dose-rate radiobiology applications employing laser-driven ions. He received in 2017 the APS John Dawson Award for Excellence in Plasma Physics Research for pioneering applications of proton radiography in high-energy density plasma.

PostDoctoral fellow at the national institute of metrology of Germany, the PTB, since September 2020 in the working group 6.2, Dosimetry for radiation therapy and diagnostic radiology. My research focus is on dosimetry for ultra-high-pulse-dose-rate (UHPDR) electron beams, more specifically using calorimeters, ion chambers, alanine dosimeters and diamond detectors.

Pr Bourhis authored more than 350 publications, and is a world class expert in oncology and radiation oncology, along with a prominent expert for head-and-neck cancers. He has been principal investigator of numerous large clinical trials in head and neck oncology and coordinated several large-scale international collaborative meta-analyses, whose contributions have been recognized worldwide. He is also Chairman of the GORTEC, a well established international cooperative group for clinical research in head and neck oncology. Since 2012, Pr Bourhis joined Lausanne University hospital as chief of the Radiation Oncology Department and is the up-coming President of the Swiss Radiation Oncology Society (SASRO). He is currently leader in the FLASH Therapy program, a ground breaking innovative radiotherapy remarkably sparing healthy tissues while being more effective on tumors. He recently treated successfully a first patient with this technique at Lausanne University hospital.

Betina Børresen, DVM, PhD, dipl.ECVIM-CA(onco), is an associate professor of veterinary and comparative oncology at Dept. of Veterinary Clinical Sciences, University of Copenhagen. Her main research activities include translational projects involving veterinary cancer patients as models for human cancer. She is currently testing electron FLASH for treating dogs with spontaneous malignant tumors in collaboration with Lund University.

Felipe A. Calvo Manuel (June 2022) Chair Professor & Chairman. Department of Radiation Oncology. Director Proton Therapy Center. Clínica Universidad de Navarra. Universidad de Navarra. Madrid-Pamplona, Spain Education Medical Degree: Autonoma University of Madrid, Spain (1978). Radiation Oncology specialty 1983 (Residency. University Hospital Puerta de Hierro, Madrid, Spain). Postgraduate Fellow: The Royal Marsden Hospital (London, England); Hahnemann University Hospital/Children´s Hospital of Philadelphia. 1983-84. (Philadelphia, USA). PhD Degree. University of Navarra (Pamplona. Spain). 1986. Health Care Responsibilities Director (1985) Radiation Oncology Department. Clinica Universidad de Navarra (Pamplona, Spain). Attending physician (1991-93). Radiation Oncology and Nuclear Medicine. Hahnemann University (Philadelphia, USA). Professor and Chairman (1993-2017). Department of Oncology. General University Hospital Gregorio Marañon. Madrid, Spain. Professor and Chairman Department of Oncology, Medical Director Proton Therapy Center (2018- ). Clinica Universidad de Navarra. Madrid. Spain Teaching (4 ANECA credits, Agency for National Accreditation in Education) Associate Clinical Professor 1985. Associate Professor 1987. University of Navarra. Full Professor: Radiation Oncology. Hahnemann University. 1991-93. Associate Professor (1993) Radiology and Medical Physics. Complutense University (Madrid, Spain); Full Professor (1995); Chair Professor (2007-2017). Hospital Vice-Dean 2006-10 Faculty of Medicine (Complutense University) at the General University Hospital Gregorio Marañon. Chair Professor University of Navarra (2018-) Coordinator, Research and Education Unit. Clinica Universidad de Navarra. Madrid. Research (6 CNEAI credits, Agency for National Research Accreditation) Director 26 PhD thesis. Associate Researcher 8 competitive grants. Principal Investigator 5 competitive grants. Chief (2011-2017) of consolidated Research Group on “Interdisciplinary Biotechnological Oncology” (Institute of Sanitary Research Gregorio Marañon, Madrid, Spain). Coordinator (2018- ) registered research group “INTRA Interdiciplinar Teragnosis and Radiosomics” Universidad de Navarra (Spain). Publications (last 10 years): 5 books (11 co-editor), 38 chapters, 157 journal articles, 265 abstracts. Cumulative impact factor > 300; (>50% Q1). Professional Vice- President 1984-86 Spanish Society of Radiation Oncology / President 1986-92 National Commission of Radiation Oncology (Minister of Health) / President 1998 International Society of Intraoperative Radiotherapy /Patroon (2002-10) Scientific Foundation. Spanish Association Against Cancer / Educational Council (2010-) European Society for Therapeutic Radiology and Oncology / Scientific Board member (2012- ) European School of Oncology. Member Spanish Royal Academy of Medicine.

I am a PhD candidate at the GSI Helmholtz Centre for Heavy Ion Research and the Max Planck Institute for Nuclear Physics. The purpose of my project is to follow the fate of the harmful reactive species produced in a biological environment by radiolysis from different radiation qualities, in order to establish a connection between their initial yields and the early biological response. To this aim, an extension of the Monte Carlo track structure code TRAX-CHEM into the "homogeneous” biochemical stage of radiation damage (up to roughly s) is in progress.

Pierluigi Casolaro received the PhD in Physics in 2019 from the University of Naples Federico II. He worked at INFN as PI of a project on beam monitoring for radiation hardness assurance. He currently works as a Postdoc at the University of Bern where he is PI of a project on the development of new detectors for FLASH radiation therapy.